Ethic Inc. Purchases 9,766 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Ethic Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 137.9% in the 2nd quarter, Holdings Channel reports. The firm owned 16,847 shares of the biopharmaceutical company’s stock after buying an additional 9,766 shares during the quarter. Ethic Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,777,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Activest Wealth Management lifted its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the first quarter worth $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals in the first quarter worth $27,000. Colonial Trust Advisors bought a new position in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, SouthState Corp lifted its position in Regeneron Pharmaceuticals by 550.0% in the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $584.74 on Thursday. The stock has a 50-day simple moving average of $576.17 and a 200 day simple moving average of $562.42. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $959.60. The stock has a market capitalization of $61.98 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.81 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the previous year, the business posted $11.56 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on REGN shares. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a report on Monday, August 4th. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Sanford C. Bernstein lifted their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.